Vandetanib beneficial in advanced medullary thyroid cancer
In patients with advanced medullary thyroid cancer, treatment with vandetanib in the first- or second-line setting provides sustained clinical benefit, with predictors of durable response including younger age at diagnosis and absence of progression, according to a study.
